Trio Medicines Ltd (Trio) is a small pharmaceutical company, wholly owned by Hammersmith Medicines Research Ltd (HMR), a CRO founded in 1993. For details, see www.hmrlondon.com.
Trio was established in 2007 by HMR and the late Sir James Black, the inventor of β-blockers and histamine H2‑blockers, to develop a gastrin/CCK2 receptor antagonist. Since then, Trio has grown and now has a pipeline of several potential new medicines.
Trio Medicines LTD is currently focused on producing effective treatments through the targeting of G-Protein Coupled Receptors (GPCRs) for a wide range of conditions. Our therapeutic expertise spans inflammatory, respiratory and cardiovascular conditions, as well as gastric neuroendocrine tumours (an orphan disease).
For more information, please email firstname.lastname@example.org.
Trio is a registered company in England and Wales. Company No. 5616306.